Suppr超能文献

双膦酸盐、维生素D、甲状旁腺激素与颌骨骨坏死。是否存在一个缺失的环节?

Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?

作者信息

Leizaola-Cardesa Ignacio-Osoitz, Aguilar-Salvatierra Antonio, Gonzalez-Jaranay Maximino, Moreu Gerardo, Sala-Romero María-José, Gómez-Moreno Gerardo

机构信息

Department of Special Care in Dentistry,Faculty of Dentistry, University of Granada, Colegio Máximo s/n, E18071, Granada, Spain,

出版信息

Med Oral Patol Oral Cir Bucal. 2016 Mar 1;21(2):e236-40. doi: 10.4317/medoral.20927.

Abstract

BACKGROUND

It is estimated that over 190 million bisphosphonates have been prescribed worldwide. But this drug can produce adverse effects, of which osteonecrosis of the jaw and severe hypocalcemia are the most serious. It is evident that bisphosphonate administration affects multiple and diverse biochemical mediators related to bone metabolism.

MATERIAL AND METHODS

This review of literature investigates four basic parameters in patients treated with bisphosphonates - parathyroid hormone (PTH), bisphosphonates, vitamin D, calcium, and jaw osteonecrosis - which are fundamental for assessing bone metabolism and so the efficacy and correct use of the drug. The imbalances generated by vitamin D and calcium deficiencies, together with their multiple systemic repercussions, have been widely researched but the outcomes of these imbalances in relation to bisphosphonate administration are not well known, and some research has indicated that they may be associated with osteonecrosis of the jaw (ONJ).

RESULTS

The present review set out to explain the functioning of bone metabolism, the importance of different chemical mediators, the imbalances produced by incorrect use of this drug, in order to forewarn against the possible relation of these parameters with ONJ, whose physiopathology remains unknown.

CONCLUSIONS

Medical and dental clinics should keep detailed anamneses of the use of vitamin D and calcium supplements, as it is of vital importance to maintain their correct levels in blood, given that these are related to ONJ as well as other adverse effects; this procedure is also necessary in order to ensure the correct use of the drug.

摘要

背景

据估计,全球已开出超过1.9亿份双膦酸盐处方。但这种药物会产生不良反应,其中颌骨坏死和严重低钙血症最为严重。显然,双膦酸盐的使用会影响与骨代谢相关的多种不同生化介质。

材料与方法

本文献综述研究了接受双膦酸盐治疗的患者的四个基本参数——甲状旁腺激素(PTH)、双膦酸盐、维生素D、钙和颌骨坏死,这些参数对于评估骨代谢以及药物的疗效和正确使用至关重要。维生素D和钙缺乏所产生的失衡及其多种全身影响已得到广泛研究,但这些失衡与双膦酸盐使用相关的结果尚不清楚,一些研究表明它们可能与颌骨坏死(ONJ)有关。

结果

本综述旨在解释骨代谢的功能、不同化学介质的重要性、该药物使用不当所产生的失衡,以便预先警示这些参数与ONJ可能存在的关系,ONJ的病理生理学仍然未知。

结论

医疗和牙科诊所应详细记录维生素D和钙补充剂的使用情况,因为保持它们在血液中的正确水平至关重要,鉴于这些与ONJ以及其他不良反应有关;为确保药物的正确使用,这一程序也是必要的。

相似文献

1
Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?
Med Oral Patol Oral Cir Bucal. 2016 Mar 1;21(2):e236-40. doi: 10.4317/medoral.20927.
2
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Acta Clin Belg. 2018 Apr;73(2):100-109. doi: 10.1080/17843286.2017.1348001. Epub 2017 Jul 10.
3
New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
Oral Dis. 2012 Sep;18(6):580-5. doi: 10.1111/j.1601-0825.2012.01912.x. Epub 2012 Feb 20.
5
[Osteonecrosis of the jaw].
Endokrynol Pol. 2011;62 Suppl 3:4-9.
6
Antiresorptive drug-related osteonecrosis of the jaw.
Dent Clin North Am. 2014 Apr;58(2):369-84. doi: 10.1016/j.cden.2013.12.006.
8
Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates.
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22(1):e43-e57. doi: 10.4317/medoral.21477.
9
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Osteoporos Int. 2017 Mar;28(3):1145-1147. doi: 10.1007/s00198-016-3840-z. Epub 2016 Nov 20.
10
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
J Oral Maxillofac Surg. 2009 Jan;67(1):159-61. doi: 10.1016/j.joms.2008.09.015.

引用本文的文献

2
Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview.
JBMR Plus. 2023 Jun 22;7(8):e10785. doi: 10.1002/jbm4.10785. eCollection 2023 Aug.
3
The effect of vitamin D deficiency on the RANKL/OPG ratio in rats.
J Oral Biol Craniofac Res. 2022 Mar-Apr;12(2):228-232. doi: 10.1016/j.jobcr.2022.02.004. Epub 2022 Feb 22.
4
Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review.
Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24(2):e195-e203. doi: 10.4317/medoral.22691.
5
Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates.
J Clin Exp Dent. 2017 Jan 1;9(1):e141-e149. doi: 10.4317/jced.53372. eCollection 2017 Jan.
6
Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates.
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22(1):e43-e57. doi: 10.4317/medoral.21477.

本文引用的文献

2
Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates.
Bone. 2013 Nov;57(1):201-5. doi: 10.1016/j.bone.2013.08.005. Epub 2013 Aug 14.
5
Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?
Oncologist. 2012;17(8):1114-9. doi: 10.1634/theoncologist.2012-0141. Epub 2012 Jun 20.
8
Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
J Oral Maxillofac Surg. 2010 Sep;68(9):2241-7. doi: 10.1016/j.joms.2010.05.043.
10
Biomechanics/risk management (Working Group 2).
Clin Oral Implants Res. 2009 Sep;20 Suppl 4:107-11. doi: 10.1111/j.1600-0501.2009.01780.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验